CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.
Patients with inflammatory breast cancer, regardless of cancer subtype (stage IIID)
Patients with non-inflammatory breast cancer: triple-negative and HER2+ subtypes, from stage IIB to IIIA-C
Adequate health status for neoadjuvant systemic treatment
Inflammatory breast cancer stage IV
Luminal A, luminal B subtypes of non-inflammatory breast cancer
Stages I-IIA breast cancer
Inability to understand or communicate in Slovenian
Single group
Liquid biopsy
Diagnostic testAdditional liquid biopsy to monitor disease
pCR in patients with breast cancer, comparing those with ≥1 CTC, ≥1 CTC cluster, or ≥1 megakaryocyte at diagnosis to those without CTCs, megakaryocytes, or CTC clusters.
Pathological Complete Response (pCR) in patients with breast cancer, comparing those with ≥1 CTC, ≥1 CTC cluster, or ≥1 megakaryocyte at diagnosis to those without CTCs, megakaryocytes, or CTC clusters.
pCR in patients with breast cancer, comparing those with ≥1 CTC, ≥1 CTC cluster, or ≥1 megakaryocyte at diagnosis to those without CTCs, megakaryocytes, or CTC clusters.
Pathological Complete Response (pCR) in patients with breast cancer, comparing those with ≥1 CTC, ≥1 CTC cluster, or ≥1 megakaryocyte at diagnosis to those without CTCs, megakaryocytes, or CTC clusters.
pCR in patients with breast cancer, comparing those with ≥1 CTC, ≥1 CTC cluster, or ≥1 megakaryocyte at diagnosis to those without CTCs, megakaryocytes, or CTC clusters.
Pathological Complete Response (pCR) in patients with breast cancer, comparing those with ≥1 CTC, ≥1 CTC cluster, or ≥1 megakaryocyte at diagnosis to those without CTCs, megakaryocytes, or CTC clusters.
pCR in patients with breast cancer, comparing those with ≥1 CTC, ≥1 CTC cluster, or ≥1 megakaryocyte at diagnosis to those without CTCs, megakaryocytes, or CTC clusters.
Pathological Complete Response (pCR) in patients with breast cancer, comparing those with ≥1 CTC, ≥1 CTC cluster, or ≥1 megakaryocyte at diagnosis to those without CTCs, megakaryocytes, or CTC clusters.
Relapse-Free Survival (RFS)
RFS in patients who are - free of CTCs or CTC clusters at the end of neoadjuvant chemotherapy, comparing their outcomes with patients who still have CTCs or CTC clusters
Relapse-Free Survival (RFS)
RFS in patients who are - free of CTCs or CTC clusters after surgery, comparing them with those who still have CTCs or CTC clusters
Overall Survival (OS)
OS in patients who are - free of CTCs or CTC clusters at the end of neoadjuvant chemotherapy, comparing their outcomes with patients who still have CTCs or CTC clusters
Overall Survival (OS)
OS in patients who are - free of CTCs or CTC clusters after surgery, comparing them with those who still have CTCs or CTC clusters
Click on the lead sponsor to view all of their trials.
